التفاصيل البيبلوغرافية
العنوان:
Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion
المؤلفون:
Andrew T. Hattersley , Bernard Thorens
المصدر:
New England Journal of Medicine, vol. 373, no. 10, pp. 974-976
سنة النشر:
2015
مصطلحات موضوعية:
medicine.medical_specialty , Glucagon , Alpha cell , chemistry.chemical_compound , Sodium-Glucose Transporter 1 , Glucosides , Sodium-Glucose Transporter 2 , Internal medicine , Benzhydryl Compounds/pharmacology , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Glucagon/secretion , Glucagon-Secreting Cells/metabolism , Glucose/metabolism , Glucosides/pharmacology , Humans , Sodium-Glucose Transporter 1/metabolism , Sodium-Glucose Transporter 2/antagonists & inhibitors , Sodium-Glucose Transporter 2/metabolism , medicine , Dapagliflozin , Benzhydryl Compounds , Sodium-Glucose Transporter 2 Inhibitors , Kidney , Reabsorption , business.industry , Glucose transporter , General Medicine , 3. Good health , Renal glucose reabsorption , medicine.anatomical_structure , Endocrinology , Glucose , chemistry , Diabetes Mellitus, Type 2 , Glucagon-Secreting Cells , business
الوصف:
Dapagliflozin targets the sodium-coupled glucose transporter type 2 in the renal proximal tubule, preventing the reabsorption of glucose into the blood. It also has a direct effect on the islet alpha cell, which may counter its effect on glucose reabsorption in the kidney.
وصف الملف:
application/pdf
اللغة:
English
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48e7151acd5054c3a1711d236ea76a9c https://serval.unil.ch/resource/serval:BIB_DA645CAAB37A.P001/REF.pdf
حقوق:
OPEN
رقم الأكسشن:
edsair.doi.dedup.....48e7151acd5054c3a1711d236ea76a9c
قاعدة البيانات:
OpenAIRE
